Workflow
TIDES业务服务
icon
Search documents
药明康德(603259):业绩延续快速增长,在手订单维持高速增长
HUAXI Securities· 2025-07-30 14:12
Investment Rating - The investment rating for the company is "Buy" [3][6]. Core Insights - The company has demonstrated rapid growth in performance, with a significant increase in revenue and net profit for the first half of 2025. Revenue reached 20.799 billion yuan, a year-on-year increase of 20.64%, while net profit attributable to shareholders grew by 101.92% to 8.561 billion yuan [1][2]. - The company's order backlog remains strong, with a total of 56.69 billion yuan in orders as of June 2025, reflecting a year-on-year growth of 37.2%, which supports future revenue growth [2]. - The TIDES business segment has shown exceptional performance, achieving revenue of 5.03 billion yuan in the first half of 2025, a remarkable year-on-year increase of 141.6% [5]. - The chemical drug D&M business has also recovered well, with revenue of 8.68 billion yuan, marking a year-on-year growth of 17.5% [5]. Financial Summary - The company adjusted its revenue forecasts for 2025-2027, with expected revenues of 44.331 billion yuan, 51.087 billion yuan, and 59.245 billion yuan respectively, reflecting a positive outlook [3][8]. - The earnings per share (EPS) estimates for 2025-2027 have been revised to 5.12 yuan, 5.27 yuan, and 6.21 yuan respectively, indicating strong growth potential [3][8]. - The company's gross margin is projected to improve, reaching 44.9% in 2025 and increasing to 46.3% by 2027 [8]. Business Segments - The TIDES business continues to be a key driver of performance, with a 48.8% year-on-year increase in the order backlog as of June 2025, and an increase in the number of clients served [5]. - The chemical drug D&M segment has added 412 new molecules to its pipeline in the first half of 2025, including four projects in Phase III and four commercial projects, indicating a growing demand [5]. Market Position - The company's total market capitalization is approximately 283.919 billion yuan, with a free float market capitalization of the same amount [3]. - The stock has shown a 52-week high of 102.49 yuan and a low of 36.86 yuan, indicating significant volatility and potential for growth [3].